Syntis
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
135 Morrissey Blvd Ste 101A, Boston, Mas...Phone Number
(857) 675-1109Website
syntis.bioRevenue
$5.7 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Syntis
Syntis Bio is a clinical-stage biopharmaceutical company developing oral therapies that harness the small intestines unique biology to provide more accessible, effective and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the worlds most prevalent conditions. Syntis is rapidly advancing a pipeline of oral therapies engineered for targeted activity in the small intestine, the bodys nexus for metabolic control, digestion and drug absorption. Alongside its lead obesity program, SYNT-101, the company is advancing a portfolio of therapies targeting orphan metabolic diseases and intestinal-related disorders. Syntis is headquartered in Boston, MA.Explore more
Syntis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Syntis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Syntis is spiking on competitors!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Syntis has new funding data
Syntis, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Syntis has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Syntis
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Syntis launches new products
Click to see if Syntis had a recent Job posting/layoffs
Earning: See what the market has to say on Syntis recently announced quarterly report
Recommended Actions
Find VP level buyers at Syntis
Find 2 more new buyers
Compare Similar Companies to Syntis
Compare insights from companies similar to Syntis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Syntis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Syntis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Syntis.
Syntis financials insights
Gather financial insights about Syntis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Seed
$15.5M
2025
Multiple Rounds
$63M
Syntis Tech Stack
A closer look at the technologies used by Syntis
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Funding
Funding
Funding
, according to a recent Form D filing, has secured $24,983,429 in Stock/Share Issuance funding.
Funding
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Syntis News & Media
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Syntis
Sign Up For FreeTo access detailed company insights
Syntis Bio is a clinical-stage biopharmaceutical company developing oral therapies that harness the small intestines unique biology to provide more accessible, effective and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the worlds most prevalent conditions. Syntis is rapidly advancing a pipeline of oral therap... Read More
